Jatenzo Cardiovascular Impact Long-Term: What the Evidence Shows

Why Cardiovascular Risk Is Central to the Jatenzo Conversation

Jatenzo is the first oral testosterone product approved in the United States that achieves consistent physiologic serum levels without relying on hepatic first-pass metabolism. That pharmacokinetic advantage is real. So is the cardiovascular signal that prompted the FDA to require a black-box warning at approval.

Understanding whether that warning reflects a molecule-specific liability or a class effect shared by all testosterone formulations is the central clinical question for prescribers. The short answer: the blood pressure effect appears partly formulation-specific, driven by the high-fat meal requirement and the high daily doses needed for adequate absorption. The longer-term cardiovascular picture remains an area of active investigation.

The FDA Black-Box Warning: Exactly What It Says

The prescribing information for Jatenzo states that the drug "can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death." [1] The label explicitly contraindicates Jatenzo in men with serious cardiovascular disease, including prior myocardial infarction, unstable angina, or decompensated heart failure.

This is not a class-wide label shared by all testosterone formulations. The topical and injectable forms carry a different set of cardiovascular precautions. The oral undecanoate formulation's BP warning was added specifically because of the signal observed in the Swerdloff registration trial.

How Lymphatic Absorption Changes the Risk Profile

Most oral androgens historically caused hepatotoxicity because they underwent extensive first-pass liver metabolism. Jatenzo bypasses that pathway. Testosterone undecanoate is absorbed into intestinal lymphatics as a chylomicron-associated molecule, delivered into systemic circulation via the thoracic duct. [2]

This bypasses the liver but does not eliminate cardiovascular concerns. Chylomicron packaging also means absorption is entirely fat-dependent. Patients who do not take Jatenzo with a meal containing at least 19 grams of fat will absorb significantly less drug, leading to subtherapeutic testosterone levels. That dietary coupling creates real-world adherence variability that standard injectable TRT does not share.

Blood Pressure: The Primary Registered Signal

In the key Phase 3 registration trial by Swerdloff et al. (N=166, 90-day primary endpoint), mean systolic blood pressure increased by approximately 3 to 5 mmHg from baseline. [3] More clinically consequential: 25.4% of participants in the full trial required either initiation of antihypertensive therapy or escalation of an existing regimen. That figure is not a rounding error. One in four treated men needed antihypertensive intervention within the trial window.

Magnitude in Clinical Context

A 3 to 5 mmHg systolic rise sounds modest on paper. Population-level data from the SPRINT trial (N=9,361) demonstrated that reducing systolic BP by approximately 10 mmHg cut cardiovascular events by roughly 25%. [4] Working in the opposite direction, a persistent 5 mmHg elevation translates to a meaningful additive risk over a decade in men who already carry baseline cardiometabolic risk factors, which describes most hypogonadal patients.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy notes: "We recommend measuring blood pressure before initiating testosterone therapy and at 3 to 6 months after starting treatment." [5] That recommendation predates Jatenzo's approval but applies directly to the oral formulation, where the BP signal is quantitatively larger than what was observed in registry data for transdermal testosterone.

Mechanistic Drivers of BP Elevation

The exact mechanism is not fully characterized. Several pathways are plausible:

• Sodium and water retention via androgen receptor activation in renal tubular cells
• Stimulation of the renin-angiotensin-aldosterone system
• Increased red blood cell mass and consequent rise in blood viscosity

The relative contribution of each pathway in the Jatenzo-specific context, versus injectable testosterone, has not been established in head-to-head mechanistic studies. The high daily doses required for oral absorption (cumulative daily doses often reaching 474 mg to 792 mg of testosterone undecanoate) may produce peak serum testosterone concentrations that transiently exceed those seen with standard transdermal dosing, potentially amplifying the BP and erythropoietic effects. [1]

Hematocrit and Polycythemia: The Secondary Erythropoietic Signal

Testosterone stimulates renal erythropoietin secretion, increasing red blood cell mass across all formulations. Jatenzo is no exception. The FDA label flags polycythemia, defined as hematocrit above 54%, as a dose-dependent adverse effect requiring dose reduction, treatment interruption, or therapeutic phlebotomy. [1]

Why Elevated Hematocrit Matters for the Heart

Hematocrit above 52% raises whole-blood viscosity. Increased viscosity is associated with higher shear stress on arterial walls, impaired microvascular flow, and a prothrombotic state. A meta-analysis of cohort studies (Franchini et al., Thrombosis Research, referenced in multiple Cochrane reviews on testosterone and vascular outcomes) found that polycythemia is an independent risk factor for venous thromboembolism, particularly in men with other predisposing factors. [6]

For a hypogonadal patient already at elevated cardiovascular risk, the combination of rising blood pressure and rising hematocrit represents compounding risk. Neither alone may be sufficient to trigger intervention, but their combination likely is.

Monitoring Protocol for Hematocrit

The Endocrine Society guideline recommends checking hematocrit at baseline, 3 to 6 months after initiation, and then annually. [5] If hematocrit rises above 54%, the guideline recommends stopping therapy until it falls to a safe level, then restarting at a lower dose. Jatenzo's minimum available dose is 158 mg twice daily; if that dose does not maintain eugonadal testosterone while keeping hematocrit below 52%, the prescriber must weigh continued therapy against accumulated erythropoietic risk.

Lipid Effects: HDL Reduction and Cardiovascular Implications

Oral testosterone formulations have consistently shown greater reductions in HDL cholesterol than injectable or transdermal forms. Even though Jatenzo bypasses hepatic first-pass metabolism, the registration trial data showed a mean HDL-C decrease of approximately 9 to 10% from baseline over 6 months. [3]

LDL and Triglycerides

LDL-C changes in the Swerdloff trial were modest and not statistically significant at group level. Triglycerides showed mixed results across individual patients, partly because the mandatory high-fat meal requirement transiently elevates postprandial triglycerides on its own. Interpreting a fasting lipid panel in a patient taking Jatenzo requires clarity about whether the blood draw was truly fasting and whether it occurred in the morning before the first dose.

HDL Reduction in the Broader Testosterone Literature

The TOM (Testosterone in Older Men with Mobility Limitations) trial was stopped early after 6 months because of increased cardiovascular events in the testosterone arm, though that trial used a gel formulation and enrolled men with high baseline CV risk. [7] HDL-C changes were not the sole driver, but combined lipid and erythropoietic effects likely contributed. Extrapolating directly to Jatenzo is not scientifically valid, but the trial illustrates that cardiovascular signals in testosterone research have emerged suddenly and unexpectedly before, underscoring the need for ongoing monitoring rather than a set-and-forget prescribing approach.

TRAVERSE Trial: The Most Relevant Long-Term Dataset

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) randomized 5,246 hypogonadal men aged 45 to 80 years with elevated cardiovascular risk to testosterone gel 1.62% or placebo for a median of 22 months. [8] The primary endpoint was MACE (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke).

What TRAVERSE Found

TRAVERSE demonstrated non-inferiority of testosterone to placebo for MACE, with event rates of 7.0% versus 7.3%, respectively (hazard ratio 0.96, 95% CI 0.78 to 1.17). [8] This was widely reported as cardiovascular "clearance" for testosterone therapy.

The more nuanced reading: TRAVERSE enrolled men using transdermal gel, not oral testosterone undecanoate. Blood pressure changes in the gel arm were smaller than those observed with Jatenzo. Rates of atrial fibrillation were statistically higher in the testosterone arm of TRAVERSE (3.5% vs. 2.4%; P<0.05). [8] Pulmonary embolism was also numerically higher in the testosterone group. These secondary findings did not reach the pre-specified MACE composite but are relevant when counseling a patient about total cardiovascular risk.

Directly applying TRAVERSE non-inferiority data to Jatenzo is a category error. The formulation, the dose, the BP trajectory, and the hematocrit trajectory differ meaningfully between gel and oral undecanoate.

Head-to-Head Formulation Comparisons: What Does Not Exist Yet

No randomized controlled trial has compared Jatenzo directly to injectable testosterone cypionate or transdermal testosterone gel on cardiovascular endpoints. This is the central evidence gap. The FDA's approval was based on testosterone normalization, not on cardiovascular outcome data, and the post-marketing requirement for a cardiovascular outcomes study has not yet produced published long-term results.

The table below summarizes the known cardiovascular signal differences across common TRT formulations, based on existing trial data, and should guide individualized formulation selection.

| Formulation | BP Signal | HDL Reduction | Hematocrit Risk | Hepatotoxicity | |---|---|---|---|---| | Jatenzo (oral TU) | Moderate-high (+3 to +5 mmHg systolic) | ~10% decrease | Present | Low (lymphatic absorption) | | Testosterone cypionate (IM) | Moderate | Mild decrease | Present (higher with weekly dosing) | Minimal | | Testosterone gel 1.62% | Low-moderate | Minimal | Lower than injectable | None | | Testosterone pellets | Moderate | Minimal data | Present | None |

Contraindications and High-Risk Populations

The Jatenzo label identifies these absolute contraindications relevant to cardiovascular health: [1]

• Serious cardiovascular disease (recent MI, unstable angina, decompensated CHF)
• Uncontrolled hypertension (blood pressure above 165/100 mmHg at baseline is a practical clinical threshold, though the label does not specify a numerical cutoff)
• Male patients with prostate or breast cancer

High-risk populations who can technically receive Jatenzo but require more intensive monitoring include men with:

• Controlled hypertension on one or more antihypertensive agents (anticipate possible up-titration)
• Baseline hematocrit between 48% and 51%
• Obstructive sleep apnea (OSA amplifies erythropoietic effects of testosterone)
• Type 2 diabetes with existing nephropathy or retinopathy
• Body mass index above 35 kg/m² (higher baseline CV risk and greater OSA prevalence)

Practical Cardiovascular Monitoring Protocol

Given the specific BP and hematocrit signals for Jatenzo, the following monitoring schedule is clinically appropriate. It integrates Endocrine Society guideline recommendations [5] with the Jatenzo-specific label requirements [1]:

Baseline Assessment (Before First Dose)

• Seated blood pressure (two readings, two minutes apart); defer initiation if above 165/100 mmHg
• Complete blood count with hematocrit
• Fasting lipid panel
• Serum testosterone (morning draw, 8 to 10 a.m.)
• 12-lead ECG in men above age 50 or with known cardiac disease
• Sleep apnea screening using STOP-BANG questionnaire

Month 3 Assessment

• Repeat seated BP (both arms if first-visit BP was borderline)
• Repeat serum testosterone (draw 3 to 5 hours post-dose for Jatenzo, which corresponds to approximate Cmax)
• CBC with hematocrit
• Dose titration decision based on testosterone and hematocrit results

The Swerdloff trial protocol used a 3-month primary endpoint partly because Jatenzo reaches steady-state testosterone exposure within 4 weeks, meaning the BP and hematocrit effects visible at 3 months represent a stable drug-effect signal rather than transient pharmacokinetic overshoot. [3]

Ongoing Annual Monitoring

• Fasting lipid panel
• CBC with hematocrit
• Blood pressure at each visit
• Serum testosterone if symptom recurrence or adherence concern

Interaction With Antihypertensive Therapy

Approximately one quarter of men in the registration trial needed new or escalated antihypertensive treatment. The most common antihypertensive additions in TRT-treated men are ACE inhibitors and angiotensin receptor blockers, which address both the renin-angiotensin pathway stimulation and the renal sodium retention component. [9]

Beta-blockers are less preferred as first additions because they do not directly address the RAAS mechanism and may reduce exercise tolerance in men whose primary motivation for TRT includes restoration of physical capacity.

Diuretics, particularly spironolactone, carry a clinical tension: spironolactone is an androgen receptor antagonist and can blunt the therapeutic effect of testosterone therapy while lowering blood pressure. If a clinician adds spironolactone to a Jatenzo regimen, monitoring for symptomatic hypogonadism recurrence is necessary.

Atrial Fibrillation: An Emerging Signal

The TRAVERSE trial's finding of higher atrial fibrillation rates in the testosterone arm (3.5% vs. 2.4%) [8] was not anticipated based on earlier, smaller trials. Atrial fibrillation was not a pre-specified secondary endpoint. A secondary analysis published in JAMA Cardiology in 2024 confirmed the signal but could not establish causality from the trial design alone.

Testosterone's electrophysiologic effects on cardiac ion channels, particularly L-type calcium channels and potassium rectifier channels, have been studied in vitro. Whether these effects translate to clinically meaningful arrhythmia risk at physiologic replacement doses is not settled. Prescribers should document baseline cardiac rhythm history and consider a 12-lead ECG in men above age 60 or with palpitation symptoms before starting Jatenzo.

Venous Thromboembolism: Real Risk, Uncertain Magnitude

The FDA added a class-wide warning for venous thromboembolism (VTE) to all testosterone products in 2014. [1] The warning applies to Jatenzo. Polycythemia-driven increases in blood viscosity are the primary proposed mechanism.

A case-control study by Baillargeon et al. (NEJM, 2012) found a doubling of VTE risk in the first 6 months of testosterone therapy in older men. [10] That study predates Jatenzo and used injectable and transdermal formulations, but the hematocrit mechanism is formulation-agnostic. Men with prior VTE, Factor V Leiden, or other thrombophilias should either avoid Jatenzo or receive anticoagulation guidance from a hematologist before initiation.

Putting It Together: Who Is an Appropriate Jatenzo Candidate?

Jatenzo fills a specific clinical niche: men who have confirmed symptomatic hypogonadism (morning serum testosterone <300 ng/dL on two occasions, per Endocrine Society criteria) [5] and who cannot or will not use injections or daily topical application. The oral convenience is real, particularly for men with needle aversion or occupational concerns about topical transfer.

The cardiovascular trade-off must be explicit. A man with baseline systolic blood pressure of 135 mmHg, hematocrit of 46%, and no prior cardiovascular events is a reasonable Jatenzo candidate with close monitoring. A man with systolic pressure of 158 mmHg, hematocrit of 50%, prior PE, and Class II heart failure is not.

The prescriber's conversation before initiation should cover:

• The 25.4% probability of needing antihypertensive escalation within 3 months
• The hematocrit monitoring schedule and the clinical threshold for dose reduction
• The HDL-lowering effect and its contribution to long-term atherosclerotic risk
• The absence of long-term cardiovascular outcomes data specific to the oral undecanoate formulation
• Alternatives including testosterone cypionate 200 mg IM every 2 weeks or testosterone gel 1.62%

Monitoring serum testosterone at 3 to 5 hours post-dose (approximate Cmax for Jatenzo) and at trough (just before the next dose) gives a more complete exposure picture than a single timed draw. If trough testosterone falls below 300 ng/dL, dose uptitration is appropriate. If Cmax exceeds 1,050 ng/dL, the dose should be reduced to minimize BP and erythropoietic effects. [1]